Magnetic Resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions;RM con manganese-DPDP (mangafodipir) nello studio della patologia focale solida pancreatica

Radiologia Medica

Volumn 108, Issue 3, 2004, Pages 194-207

  Zanello, Alessandro ^a,b   Nicoletti, Roberto ^a   Brambilla, Paolo ^a   Boccuni, Riccardo ^a   Carlo, Valerio D I ^a   Staudacher, Carlo ^a   Del Maschio, Alessandro ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Contrast media; Neoplasm Magnetic Resonance; Pancreas

Indexed keywords

MANGAFODIPIR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG INFUSION; DRUG UPTAKE; ECHOGRAPHY; FEMALE; FOCAL SOLID PANCREATIC LESION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS INJURY; PANCREATITIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

ADULT; AGED; CONTRAST MEDIA; EDETIC ACID; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PYRIDOXAL PHOSPHATE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 6044239422     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kern S, Hruban R, Hollingsworth MA et al: A white paper: the product of a pancreas cancer Think Tank. Cancer Res 61: 4923-4932, 2001.
2. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
3. Di Carlo V, Andreoni B, Zerbi A: Neoplasie del pancreas. In Staudacher V, Andreoni B, Veronesi U, Costa A (Eds): Manuale di oncologia chirurgica, pp. 429-439. III edizione. Masson, Milano, 1994.
4. Hamm B, Vogl TJ, Branding G et al: Focal liver lesions: MR imaging with Mn-DPDP - Initial clinical results in 40 patients. Radiology 182: 167-174, 1992.
5. Elizondo G, Fretz CJ, Stark DD et al: Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178: 73-78, 1991.
6. Toft KG, Hustvedt SO, Grant D et al: Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol 38: 677-689, 1997.
7. Wang C, Gordon PB, Hustvedt SO et al: MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol 38: 665-676, 1997.
8. Wang C, Johansson L, Western A et al: Sequence optimization in Mangafodipir trisodium-enhanced liver and pancreas MRI. J Magn Reson Imaging 9: 280-284, 1999.
9. Ahlström H, Gehl HB: Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging. Acta Radiol 38: 660-664, 1997.
10. Gehl HB, Vorwerk D, Klose KC et al: Pancreatic enhancement after low-dose infusion of MnDPDP. Radiology 180: 337-339, 1991.
11. Gehl HB, Urhahn R, Bohndorf K et al: Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. Radiology 186: 795-798, 1993.
12. Diehl SJ, Lehmann KJ, Gaa J et al: MR imaging of pancreatic lesions: comparison of Manganese-DPDP and Gadolinium chelate. Invest Radiol 34: 589-595, 1999.
13. Galli G: Guida alla statistica nelle scienze radiologiche. Ecoedizioni internazionali: 190-193, 2002.
14. Moss AA, Gamsu G, Genant HK: Computed Tomography of the body. W. B. Saunders Company 901-912, 1992.
15. Gabata T, Matsui O, Kadoya M et al: Small pancreatic adenocarcinoma: efficacy of MR imaging with fat suppression and gadolinium enhancement. Radiology 193: 683-688, 1994.
16. Ichikawa T, Haradome H, Hachiya J et al: Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 202: 655-662, 1997.
17. Megibow AJ, Zhou XH, Rotterdam H et al: Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability. Report of the Radiology Diagnostic Oncology Group. Radiology 195: 327-332, 1995.
18. Nishiharu T, Yamashita Y, Abe Y et al: Local extension of pancreatic carcinoma: assessment with thin-section helical CT versus with breath-hold fast MR imaging - ROC analysis. Radiology 212: 445-452, 1999.
19. Vellet AD, Romano W, Bach DB et al: Adenocarcinoma of the pancreatic ducts: comparative evaluation with CT and MR imaging at 1.5 T. Radiology 183: 87-95, 1992.
20. Lim KO, Stark DD, Leese PT et al: Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology 178: 79-82, 1991.
21. Kettritz U, Warshauer DM, Brown ED et al: Enhancement of the normal pancreas: comparison of manganese-DPDP and gadolinium chelate. Eur Radiol 6: 14-18, 1996.
22. Mayo-Smith WW, Schima W, Saini S et al: Pancreatic enhancement and pulse sequence analysis using low-dose Mangafodipir Trisodium. AJR 170: 649-652, 1998.
23. Schima W, Fugger R: Evaluation of focal pancreatic masses: comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT. Eur Radiol 12: 2998-3008, 2002.
24. Romijn MG, Stoker J, van Eijck CH et al: MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer. J Magn Reson Imaging 12: 261-268, 2000.
25. Rieber A, Tomczak R, Nüssle K et al: MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT. Br J Radiol 73: 1165-1169, 2000.
26. Mathieu D, Coffin C, Kobeiter H et al: Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. J Magn Reson Imaging 10: 193-195, 1999.